Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome

Dorothee S. Stichweh, Marilynn Punaro, Virginia Pascual

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF α), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.

Original languageEnglish (US)
Pages (from-to)262-265
Number of pages4
JournalPediatric Dermatology
Volume22
Issue number3
DOIs
StatePublished - May 2005

Fingerprint

Pyoderma Gangrenosum
Therapeutic Uses
Inflammatory Bowel Diseases
Carrier Proteins
Necrosis
Monoclonal Antibodies
Observation
Mutation
Genes
Pyogenic arthritis, pyoderma gangrenosum, and acne
Infliximab
Therapeutics

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. / Stichweh, Dorothee S.; Punaro, Marilynn; Pascual, Virginia.

In: Pediatric Dermatology, Vol. 22, No. 3, 05.2005, p. 262-265.

Research output: Contribution to journalArticle

Stichweh, Dorothee S. ; Punaro, Marilynn ; Pascual, Virginia. / Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. In: Pediatric Dermatology. 2005 ; Vol. 22, No. 3. pp. 262-265.
@article{33b9ab75b8354220bea963c8f18464dd,
title = "Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome",
abstract = "Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF α), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.",
author = "Stichweh, {Dorothee S.} and Marilynn Punaro and Virginia Pascual",
year = "2005",
month = "5",
doi = "10.1111/j.1525-1470.2005.22320.x",
language = "English (US)",
volume = "22",
pages = "262--265",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome

AU - Stichweh, Dorothee S.

AU - Punaro, Marilynn

AU - Pascual, Virginia

PY - 2005/5

Y1 - 2005/5

N2 - Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF α), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.

AB - Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF α), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.

UR - http://www.scopus.com/inward/record.url?scp=19644375183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19644375183&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1470.2005.22320.x

DO - 10.1111/j.1525-1470.2005.22320.x

M3 - Article

C2 - 15916580

AN - SCOPUS:19644375183

VL - 22

SP - 262

EP - 265

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 3

ER -